This publication is now 25% off the original price of $3250. Now just $2437.
The need for new agents to fight drug-resistant bacteria is creating both challenges and significant market opportunities for pharmaceutical manufacturers and biotechnology companies. Divided into two primary market segments, antibacterials and antifungals, this comprehensive Kalorama Information study offers in-depth coverage of the $9 billion U.S. market for existing and emerging anti-infective drugs. Readers find detailed market analysis, including historical, current and forecast market size, for each of the market segments. Up-to-date information on products in development and their impact on the market are provided. Detailed profiles of major competitors in each market segment are also included.

Related Reports:

Diagnostic Test Service Commercialization in Multiplex and Esoteric Testing: A Roadmap to Diagnostics in the 21st Century
Aug 1, 2008 - KLI1806317 - $3,500.00

Anesthesia Drugs: Worldwide Markets
Jul 1, 2007 - KLI1399472 - $2,995.00

Global Tuberculosis Diagnostics and Treatment Markets
Jun 1, 2007 - KLI1399459 - $3,995.00

Anti-Infectives: World Market, 2nd Edition, Vol III: Antivirals
May 1, 2007 - KLI1399456 - $2,995.00

Anti-Infectives: World Markets, 2nd Edition, Vol. I-III (Complete Series)
May 1, 2007 - KLI1477668 - $5,995.00

Anti Infectives: World Market, 2nd Edition, Vol II: Antibacterials
Apr 1, 2007 - KLI1399449 - $2,995.00

Anti-Infectives: World Market, 2nd. Ed., Vol. I: Antifungals
Mar 1, 2007 - KLI1399435 - $2,995.00

Critical Care Pharmaceutical Markets: A Strategic Analysis
Jun 1, 2006 - KLI1189532 - $2,995.00

The Future of Biotechnology Instrumentation
Jan 1, 2006 - KLI1186403 - $2,995.00

The U.S. Market for Over-the-Counter Anti-Infectives
Jan 1, 2006 - KLI1170066 - $3,000.00